<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473499</url>
  </required_header>
  <id_info>
    <org_study_id>BBM-VS54-HOM</org_study_id>
    <nct_id>NCT00473499</nct_id>
  </id_info>
  <brief_title>PEPCAD III Substudy: Stem Cell Mobilization</brief_title>
  <acronym>PEPCADIIIsub</acronym>
  <official_title>Paclitaxel-Eluting PTCA-Balloon in Combination With the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease - Substudy Homburg/Saar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the PEPCAD III substudy is to assess the efficacy of the Paclitaxel-eluting DEBlue
      stent system in the treatment of stenoses in native coronary arteries compared to the
      Sirolimus-eluting Cypher stent by intravascular ultrasound (IVUS) and to study the influence
      of both devices on endothelial function, coronary flow reserve, and stem cell mobilization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the PEPCAD III substudy is to assess the efficacy of the DEBlue®
      Paclitaxel-eluting stent system in the treatment of stenoses in native coronary arteries
      compared to the Sirolimus-eluting Cypher stent by intravascular ultrasound (IVUS) and to
      study the influence of both devices on endothelial function, coronary flow reserve, and stem
      cell mobilization. This study is a prospective, randomized, single-center, two-armed phase-II
      study. During the PEPCAD III trial, 40 patients of the Homburg / Saar center will be randomly
      assigned to ei-ther one of the treatment groups (20 patients treated with DEBlue, 20 patients
      with Cypher®). Patients with stable or selected forms of unstable angina or documented
      ischemia due to a significant lesion in a native coronary artery will be included. Vessels
      may not supply an en-tirely infarcted myocardial area. Additional 20 patients receiving
      uncoated stents (Coroflex® Blue, B.Braun) will undergo the same diagnostic procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stem cell mobilization and differentiation</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>endothelial function</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>late lumen loss</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>DEBlue stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel coated balloon with CoCr stent mounted on it</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cypher stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Coroflex Blue stent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEBlue vs Cypher vs BMS</intervention_name>
    <description>BMS vs DES vs DEB+BMS</description>
    <arm_group_label>DEBlue stent</arm_group_label>
    <arm_group_label>Cypher stent</arm_group_label>
    <arm_group_label>Coroflex Blue stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable or unstable angina or documented ischemia due to a significant
             lesion in a native coronary artery

          -  Patients eligible for coronary revascularization by means of PCI

          -  Intention to treat one lesion with one stent

          -  Patients suitable for coronary revascularization of any sort (balloon angioplasty,
             device-assisted balloon-angioplasty, or coronary artery bypass grafting)

          -  Patients must be ≥ 18 years of age

          -  Women of childbearing potential may not be pregnant nor have the desire to becoming
             pregnant during the first year following the study procedure. Hence, patients will be
             advised to use an adequate birth control method up to and including 9 months follow-up

          -  Patients who are mentally and linguistically able to understand the aim of the study
             and to show sufficient compliance in following the study protocol

          -  Patients must agree to undergo the 9 months angiographic follow-up

          -  Patients must agree to undergo the 1 and 3 year clinical follow-up

          -  Patient is able to verbally acknowledge an understanding of the associated risks,
             benefits, and treatment alternatives to therapeutic options of this trial, e.g.
             balloon angioplasty by means of the Paclitaxel-eluting PTCA-balloon catheter in
             combination with the Coroflex BlueTM stent or the Sirolimus-eluting CypherTM stent.
             The patients, by providing informed consent, agree to these risks and benefits as
             stated in the patient informed consent document.

          -  Significant stenoses in native coronary arteries with nominal stent diameters between
             ≥ 2.5 mm and ≤ 3.5 mm and &lt; 24 mm in length

        Exclusion Criteria:

          -  Unprotected left main

          -  In stent restenosis

          -  Indication for more than one lesion to treat, even as staged procedure

          -  Intended bifurcational stenting

          -  Patients requiring chronic anticoagulation

          -  SVG and AG

          -  Acute MI (STEMI, NSTEMI)

          -  Cardiogenic shock

          -  Chronic total occlusions

          -  Pregnancy

          -  Patients with stand alone balloon angioplasty, or stent deployment 6 months prior to
             enrolment into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Scheller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes, Homburg/Saar, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg / Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Scheller B, Speck U, Böhm M. Prevention of restenosis: is angioplasty the answer? Heart. 2007 May;93(5):539-41.</citation>
    <PMID>17435062</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. Epub 2006 Nov 13.</citation>
    <PMID>17101615</PMID>
  </reference>
  <reference>
    <citation>Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M, Hamm B. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006 Aug;240(2):411-8.</citation>
    <PMID>16864669</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004 Aug 17;110(7):810-4. Epub 2004 Aug 9.</citation>
    <PMID>15302790</PMID>
  </reference>
  <reference>
    <citation>Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, Shimizu M, Komoda H, Node K. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation. 2007 Feb 6;115(5):553-61. Epub 2007 Jan 29.</citation>
    <PMID>17261663</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2007</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Bruno Scheller</name_title>
    <organization>University Hospital, Saarland</organization>
  </responsible_party>
  <keyword>drug eluting balloon</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

